|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2006-12-7
|
|
pubmed:abstractText |
There is now increasing evidence that a constitutive expression of cyclooxygenase (COX)-2 plays a role in the development and progression of malignant epithelial tumors. Expression of COX-2 is seen in 93% of melanomas, as determined by immunohistochemistry. Temozolomide (TMZ) has demonstrated activity against melanoma and has been investigated as single agent or in combination. We designed a phase II study to assess the efficacy and toxicity of the combination of TMZ and celecoxib (a COX-2 inhibitor) in patients with advanced melanoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:FountzilasGG,
pubmed-author:FrangiaKK,
pubmed-author:GogasHH,
pubmed-author:MantzouraniMM,
pubmed-author:MarkopoulosCC,
pubmed-author:MiddletonMM,
pubmed-author:PanagiotouPP,
pubmed-author:PapadopoulosOO,
pubmed-author:PectasidesDD,
pubmed-author:PolyzosAA,
pubmed-author:StavrinidisII,
pubmed-author:TsoutsosDD,
pubmed-author:VaiopoulosGG
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1835-41
|
|
pubmed:meshHeading |
pubmed-meshheading:16980601-Antineoplastic Agents, Alkylating,
pubmed-meshheading:16980601-Brain Neoplasms,
pubmed-meshheading:16980601-Cyclooxygenase 2,
pubmed-meshheading:16980601-Cyclooxygenase Inhibitors,
pubmed-meshheading:16980601-Dacarbazine,
pubmed-meshheading:16980601-Female,
pubmed-meshheading:16980601-Humans,
pubmed-meshheading:16980601-Immunohistochemistry,
pubmed-meshheading:16980601-Male,
pubmed-meshheading:16980601-Melanoma,
pubmed-meshheading:16980601-Middle Aged,
pubmed-meshheading:16980601-Neoplasm Metastasis,
pubmed-meshheading:16980601-Pyrazoles,
pubmed-meshheading:16980601-Skin Neoplasms,
pubmed-meshheading:16980601-Sulfonamides,
pubmed-meshheading:16980601-Survival Analysis
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
|
|
pubmed:affiliation |
First Department of Medicine, University of Athens, Medical School, Athens, Greece. hgogas@hol.gr
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
